Clinical Laserthermia Systems AB (publ)
Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. It offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. The company also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers that provides multiple options to control trea… Read more
Clinical Laserthermia Systems AB (publ) (CLS-B) - Net Assets
Latest net assets as of December 2025: Skr66.48 Million SEK
Based on the latest financial reports, Clinical Laserthermia Systems AB (publ) (CLS-B) has net assets worth Skr66.48 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr76.49 Million) and total liabilities (Skr10.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr66.48 Million |
| % of Total Assets | 86.92% |
| Annual Growth Rate | 18.56% |
| 5-Year Change | 213.83% |
| 10-Year Change | 289.61% |
| Growth Volatility | 112.78 |
Clinical Laserthermia Systems AB (publ) - Net Assets Trend (2008–2025)
This chart illustrates how Clinical Laserthermia Systems AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Clinical Laserthermia Systems AB (publ) (2008–2025)
The table below shows the annual net assets of Clinical Laserthermia Systems AB (publ) from 2008 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr66.48 Million | +1.21% |
| 2024-12-31 | Skr65.69 Million | +50.91% |
| 2023-12-31 | Skr43.53 Million | +453.44% |
| 2022-12-31 | Skr7.87 Million | -62.87% |
| 2021-12-31 | Skr21.18 Million | +52.10% |
| 2020-12-31 | Skr13.93 Million | +99.06% |
| 2019-12-31 | Skr7.00 Million | -85.95% |
| 2018-12-31 | Skr49.81 Million | +50.95% |
| 2017-12-31 | Skr33.00 Million | +93.37% |
| 2016-12-31 | Skr17.06 Million | -12.32% |
| 2015-12-31 | Skr19.46 Million | -38.37% |
| 2014-12-31 | Skr31.58 Million | +21.03% |
| 2013-12-31 | Skr26.09 Million | +52.62% |
| 2012-12-31 | Skr17.09 Million | +57.83% |
| 2011-12-31 | Skr10.83 Million | +4.57% |
| 2010-12-31 | Skr10.36 Million | +56.26% |
| 2009-12-31 | Skr6.63 Million | +80.23% |
| 2008-12-31 | Skr3.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Clinical Laserthermia Systems AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1297233500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr71.98 Million | 103.32% |
| Other Comprehensive Income | Skr1.85 Million | 2.65% |
| Other Components | Skr9.64 Million | 13.83% |
| Total Equity | Skr69.67 Million | 100.00% |
Clinical Laserthermia Systems AB (publ) Competitors by Market Cap
The table below lists competitors of Clinical Laserthermia Systems AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Solera National Bancorp Inc
PINK:SLRK
|
$13.78 Million |
|
Buima Group
TWO:5543
|
$13.79 Million |
|
Watos Corea Co. Ltd
KQ:079000
|
$13.79 Million |
|
Good Drinks Australia Ltd
AU:GDA
|
$13.80 Million |
|
HEBEI YICHEN GRP H YC 05
F:HE2
|
$13.78 Million |
|
Tolins Tyres Ltd
NSE:TOLINS
|
$13.78 Million |
|
Tier One Silver Inc
OTCQB:TSLVF
|
$13.78 Million |
|
Cherrybro co.Ltd
KQ:066360
|
$13.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Clinical Laserthermia Systems AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 68,722,000 to 69,667,000, a change of 945,000 (1.4%).
- Net loss of 41,612,000 reduced equity.
- New share issuances of 35,043,000 increased equity.
- Other comprehensive income decreased equity by 230,000.
- Other factors increased equity by 7,744,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-41.61 Million | -59.73% |
| Share Issuances | Skr35.04 Million | +50.3% |
| Other Comprehensive Income | Skr-230.00K | -0.33% |
| Other Changes | Skr7.74 Million | +11.12% |
| Total Change | Skr- | 1.38% |
Book Value vs Market Value Analysis
This analysis compares Clinical Laserthermia Systems AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.06x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.23x to 2.06x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | Skr24.15 | Skr5.56 | x |
| 2009-12-31 | Skr0.14 | Skr5.56 | x |
| 2010-12-31 | Skr0.23 | Skr5.56 | x |
| 2011-12-31 | Skr0.21 | Skr5.56 | x |
| 2012-12-31 | Skr1.00 | Skr5.56 | x |
| 2013-12-31 | Skr304.68 | Skr5.56 | x |
| 2014-12-31 | Skr370.43 | Skr5.56 | x |
| 2015-12-31 | Skr191.86 | Skr5.56 | x |
| 2016-12-31 | Skr147.98 | Skr5.56 | x |
| 2017-12-31 | Skr233.82 | Skr5.56 | x |
| 2018-12-31 | Skr314.28 | Skr5.56 | x |
| 2019-12-31 | Skr40.39 | Skr5.56 | x |
| 2020-12-31 | Skr63.07 | Skr5.56 | x |
| 2021-12-31 | Skr75.78 | Skr5.56 | x |
| 2022-12-31 | Skr21.29 | Skr5.56 | x |
| 2023-12-31 | Skr13.63 | Skr5.56 | x |
| 2024-12-31 | Skr6.24 | Skr5.56 | x |
| 2025-12-31 | Skr2.69 | Skr5.56 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Clinical Laserthermia Systems AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -59.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -237.96%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.10x
- Recent ROE (-59.73%) is above the historical average (-174.05%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -18.24% | -447.33% | 0.03x | 1.50x | Skr-1.04 Million |
| 2009 | -29.83% | -988.51% | 0.02x | 1.24x | Skr-2.64 Million |
| 2010 | -48.01% | -1418.90% | 0.03x | 1.14x | Skr-6.01 Million |
| 2011 | -64.40% | -1992.87% | 0.03x | 1.20x | Skr-8.06 Million |
| 2012 | -74.28% | -10311.36% | 0.01x | 1.17x | Skr-14.41 Million |
| 2013 | -70.24% | -152708.33% | 0.00x | 1.12x | Skr-20.93 Million |
| 2014 | -56.50% | 0.00% | 0.00x | 1.17x | Skr-21.00 Million |
| 2015 | -85.28% | 0.00% | 0.00x | 1.14x | Skr-18.54 Million |
| 2016 | -157.93% | -740.97% | 0.13x | 1.60x | Skr-28.66 Million |
| 2017 | -64.44% | -3460.50% | 0.01x | 1.36x | Skr-24.56 Million |
| 2018 | -65.96% | -1817.20% | 0.03x | 1.16x | Skr-37.84 Million |
| 2019 | -619.91% | -3041.73% | 0.04x | 5.53x | Skr-44.07 Million |
| 2020 | -415.99% | -4349.77% | 0.03x | 3.19x | Skr-59.33 Million |
| 2021 | -291.89% | -2833.63% | 0.03x | 3.06x | Skr-65.79 Million |
| 2022 | -766.63% | -1127.31% | 0.13x | 5.37x | Skr-71.58 Million |
| 2023 | -174.34% | -964.49% | 0.14x | 1.26x | Skr-84.37 Million |
| 2024 | -69.30% | -253.54% | 0.24x | 1.14x | Skr-54.50 Million |
| 2025 | -59.73% | -237.96% | 0.23x | 1.10x | Skr-48.58 Million |
Industry Comparison
This section compares Clinical Laserthermia Systems AB (publ)'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $76,257,140
- Average return on equity (ROE) among peers: -74.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Clinical Laserthermia Systems AB (publ) (CLS-B) | Skr66.48 Million | -18.24% | 0.15x | $13.78 Million |
| Acarix A/S (ACARIX) | $76.60 Million | -60.65% | 0.08x | $28.86 Million |
| Arcoma AB (ARCOMA) | $12.52 Million | -92.85% | 4.66x | $8.93 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $353.18 Million | -39.18% | 0.87x | $19.20 Million |
| CellaVision AB (CEVI) | $20.07 Million | 13.08% | 1.20x | $262.59 Million |
| Chordate Medical Holding AB (CMH) | $38.95 Million | -55.88% | 0.13x | $17.64K |
| Coala Life Group AB (COALA) | $52.33 Million | -287.99% | 0.53x | $468.93K |
| C-Rad AB (publ) (CRAD-B) | $93.64 Million | 22.63% | 0.57x | $56.67 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $34.43K |
| Episurf Medical AB (publ) (EPIS-B) | $41.40 Million | -170.53% | 0.39x | $5.40 Million |